Abstract: Valproic acid (VPA), an agent that is used to treat epileptic seizures, can cause spatial memory impairment in adults and children. This effect is thought to be due to the ability of VPA to inhibit neurogenesis in the hippocampus, which is required for learning. We have previously used an animal model to show that VPA significantly impairs hippocampal-spatial working memory and inhibits neuronal generation in the sub-granular zone of the dentate gyrus. As there are patient reports of improvements in memory after discontinuing VPA treatment, the present study investigated the recovery of both spatial memory and hippocampal neurogenesis at two time points after withdrawal of VPA. Male Wistar rats were given intraperitoneal injections of 0.9% normal saline or VPA (300 mg/kg) twice a day for 10 d. At 1, 30, or 45 d after the drug treatment, the novel object location (NOL) test was used to examine spatial memory; hippocampal cell division was counted using Ki67 immunohistochemistry, and levels of brain-derived neurotrophic factor (BDNF) and Notch1 were measured using western immunoblotting. Spatial working memory was impaired 1 and 30 d after the final administration, but was restored to control levels by 45 d. Cell proliferation had increased to control levels at 30 and 45 d. Both markers of neurogenesis (BDNF and Notch1 levels) had returned to control levels at 45 d. These results demonstrate that memory recovery occurs over a period of six weeks after discontinuing VPA treatment and is preceded by a return of hippocampal neurogenesis to control levels.
Introduction
Valproic acid (VPA) is commonly used to treat patients for seizures (epilepsy) and mood disorders (bipolar disorder) (Henry, 2003; Buckley, 2008) . It is also used as a medication for certain cancer and human immunodeficiency virus (HIV) therapies (Lehrman et al., 2005) . VPA modulates neuronal activity by blocking sodium and calcium channels, increasing γ-aminobutyric acid (GABA)-mediated inhibitory neurotransmission and decreasing levels of brain aspartate (Kwan et al., 2001 ). In addition, it can function to stabilize mood by enhancing the extracellular signal-regulated kinase (ERK) pathway (Hao et al., 2004) . Separate from its psychiatric effects, VPA is a potent blocker of cell proliferation. This action is mediated by the ability of VPA to inhibit histone deacetylase (HDAC) enzymes (Hsieh et al., 2004) , which regulate the degree of binding between DNA and histone proteins. Down-regulation of HDACs induces the expression of growth arrest genes including the mitotic inhibitor p21 (Li et al., 2005; Das et al., 2007) and reduces brain-derived neurotrophic factor (BDNF) expression (Bredy et al., 2007) .
Although VPA has low toxicity and a good safety profile, it causes mild to moderate cognitive impairment in over 20% of adult patients (Carpay et al., 2005; Cysique et al., 2006; Gualtieri and Johnson, 2006; Meador, 2007; Senturk et al., 2007; Bewernick and Schlaepfer, 2013; Quesseveur et al., 2013) . Aside from its effects on humans, VPA can reduce spatial working memory in adult, but not neonatal, rats shortly after administration. A probable mechanism behind the cognitive changes found after VPA treatment is a decrease in adult neurogenesis in the hippocampus (Umka et al., 2010) . Adult neurogenesis continually generates new granule cell neurons from proliferating neural stem cells in the sub-granular zone (SGZ) of the dentate gyrus, and levels of neurogenesis correlate with cognitive ability (Eriksson et al., 1998; Abrous et al., 2005; Kitabatake et al., 2007; Ehninger and Kempermann, 2008) . VPA reduces the number of dividing cells in the SGZ, as measured by Ki67 expression (Kee et al., 2002; Jessberger et al., 2007; Umka et al., 2010) . In addition, VPA reduces the levels of BDNF which is required for the survival, migration, and maturation of neural cells involved in neurogenesis, and the expression of Notch1, a receptor found in neural stem cells which regulates their proliferation (Hitoshi et al., 2002; Breunig et al., 2007; Jessberger et al., 2007; Bekinschtein et al., 2008; Chan et al., 2008) . Both BDNF and Notch1 levels are associated with cognitive performance and provide markers of neurogenesis, which may correlate with cognitive changes (Wang et al., 2004; Costa et al., 2005; Cunha et al., 2010) .
While memory improvement after the cessation of VPA treatment has been reported (Masmoudi et al., 2006; Hommet et al., 2007; Lossius et al., 2008) , the time course and association with changes in hippocampal neurogenesis have not been investigated. A rat model used in the present study shows the consequences of VPA withdrawal on memory 30 and 45 d after the end of treatment as measured by the novel object location (NOL) test, which relates to human memory (Reed and Squire, 1997; Mumby et al., 2002) .
Behavior was compared to the expression of markers of hippocampal neurogenesis.
Materials and methods

Animals and drug administration
All subjects were male Wistar rats (the National Laboratory Animal Center, Mahidol University, Salaya, Nakorn Pathom, Thailand), which were 4-5 weeks old and 180-220 g at the beginning of the procedures. Four-to five-week-old rats, equivalent in maturity to 12-year-old humans, have a brief and accelerated childhood. Animals were housed three to a cage under a 12-h light/12-h dark cycle, and food and water were given ad libitum.
Rats were randomly divided into six groups: control 10 d (n=10), control withdrawal 30 d (n=10), and control withdrawal 45 d (n=12) groups received 0.9% saline (9 g/L NaCl) injections, while VPA 10 d (n=10), VPA withdrawal 30 d (n=11), and VPA withdrawal 45 d (n=12) groups received VPA (300 mg/kg, dissolved in 0.9% normal saline; Sigma-Aldrich, Inc., St. Louis, USA) at 1 mL/kg for 10 consecutive days (Fig. 1) . The saline and VPA were administered by two daily intraperitoneal injections at about 10:00 and 14:00. This treatment regime was used as it is within the range which diminishes seizure prevalence in uncontrollably epileptic rats (Nissinen and Pitkänen, 2007) and has been used in previous studies (Hsieh et al., 2004; Umka et al., 2010) . After arrival, rats were weighed every day and acclimatized for one week before drug treatment.
Behavioral testing (NOL test)
The modified NOL test (Dix and Aggleton, 1999) was carried out as described previously (Umka et al., 2010) . The test made use of the rats' inquisitiveness and required the animals to recognize distinct objects in familiar and novel locations. The test was performed between 9:00 and 16:00 under an illumination of 350-400 lx. The test apparatus consisted of an arena (an open square opaque Perspex box, 36 cm wide×50 cm long×30 cm high). The animals were acclimated for 30 min in the arena 24 h before the test. The following day, two identical weighted water bottles (19 cm height, 6.5 cm diameter) were placed in different random locations in the arena and the rats were permitted to investigate for 3 min (familiarization trial). The rats were then returned to their cages for a 5-min inter-trial interval. During this period, the arena and the objects were wiped with 20% ethanol. In the choice trial, the rats were put back into the arena to explore for 3 min after one object had been placed in its original location whereas the other was placed in a new location. Exploratory activity such as sniffing, licking, chewing or directing their noses at the object from a distance of less than 2 cm was monitored (Dix and Aggleton, 1999) . The preference index (PI) is defined as the percentage of time spent exploring an object in the novel location over the sum of exploration time of novel and familiar locations in the choice trial (Sirichoat et al., 2015; Welbat et al., 2016a Welbat et al., , 2016c Chaisawang et al., 2017) . A PI higher than 50% chance reveals that the animals prefer the object in the novel position and were able to remember the original object locations. The time spent exploring objects in all trials was scored twice a random time and averaged from digitized recordings using a stopwatch. During the test period, the observer was not present in the room.
Brain tissue preparation
The hippocampus is a prime candidate for the site of action of VPA in causing cognitive decline as this structure is required for spatial working memory (Carrozzo et al., 2005) and recognition (Reed and Squire, 1997) . It is also one of the few sites in the adult brain where the production of new neurons continues. These newly formed granule cell neurons, which integrate into the circuitry of the dentate gyrus, are required for spatial memory consolidation (Zhao et al., 2006; Imayoshi et al., 2008) . After behavioral testing, animals were put down using rapid stunning and cervical decapitation. After removal of the brain, one half was kept for immunofluorescence staining and the hippocampus was removed from the other half and snap-frozen for western blotting. For immunofluorescence staining, the half brains were immersed in a cryoprotectant (30% sucrose) for 3 h at 4 °C before being embedded in optimum cutting temperature (OCT; Thermo Fisher Scientific, Germany), and snap-frozen in liquid nitrogen-cooled isopentane. They were then stored at −80 °C before being cut and analyzed. Frozen brains were cut into 20-μm thick consecutive sections through the whole dentate gyrus (between Bregma −2.3 to 6.3 mm) in the coronal plane using a cryostat (Cryostat series HM550 Microm international, A.S. Science, Co., Ltd., Walldorf, Germany). Sections were prepared on 3-aminopropyl-triethoxysilane (APES)-coated slides and kept at −20 °C until needed for immunofluorescence staining (Welbat et al., 2016a) . 
Immunofluorescence staining
A technique for systematic random selection (Mayhew and Burton, 1988 ) was employed to choose every 20th section from the entire dentate gyrus to obtain eight sections per brain. Ki67 staining was performed as described earlier (Umka et al., 2010) . The procedure was carried out at room temperature in a light-protected, humid environment. Briefly, sections were defrosted and preserved in 0.5% paraformaldehyde (pH 7.4) for 3 min, followed by 1 h incubation with monoclonal mouse Ki67 primary antibody (1:100, Vector Laboratory, Inc., USA). They were then washed, incubated with Alexa fluor 488 Rabbit Anti-mouse IgG (1:300, Invitrogen, USA), and counterstained with propidium iodide (Sigma-Aldrich, USA). Sections were examined at ×40 using a Nikon ECLIPSE 80i fluorescence microscope. Ki67-positive cells were counted within the SGZ, defined as cells within three cell diameters of the dentate gyrus (Umka et al., 2010) . The total number of positive cells was calculated by averaging the positive cell numbers per section and multiplying by 20 (Welbat et al., 2016a (Welbat et al., , 2016b (Welbat et al., , 2016c Chaisawang et al., 2017) .
Western immunoblotting
Hippocampal tissue was used for western immunoblotting as previously described (Mustafa et al., 2008) . The primary antibodies used as reference markers were polyclonal rabbit anti-BDNF N-20 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal goat anti-Notch1 C20 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), or monoclonal mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (1:20000; Abcam, Cambridge, UK). The secondary antibodies were polyclonal goat anti-rabbit horseradish peroxidaseconjugated secondary antibody (1:2000; Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal mouse anti-goat horseradish peroxidase-conjugated (1:2000; Cruz Biotechnology, Santa Cruz, CA, USA), and polyclonal mouse anti-rabbit horseradish peroxidaseconjugated (1:2000; Cruz Biotechnology, Santa Cruz, CA, USA). Examination of protein bands was performed using a chemiluminescence kit (Amersham GE Healthcare, Buckinghamshire, UK) and ImageQuant 400 camera system (GE Healthcare). The optical density of bands was quantified using ImageJ software. Protein expression is presented as the percentage of GAPDH expression.
Statistical analysis
All statistical parameters were calculated using GraphPad Prism 5.0 software and SPSS (V13.0), and significance was regarded as P<0.05. The normality of distributions of all data was tested using the Kolmogorov-Smirnov test. Student's unpaired t-test was used to compare exploration time of animals in familiarization and choice trials. One-way analysis of variance (ANOVA) was used to analyze PI, distance moved, proliferating cell count, and protein expression. Bonferronni's post-hoc test was performed when ANOVA was significant.
Results
Effect of VPA withdrawal on spatial working memory
The effect of VPA withdrawal on hippocampalspatial working memory was measured with the NOL test. In the familiarization trial, all the treatment groups showed no significant difference in results for the two objects in different locations, indicating that all animals showed no preference for either replica or different locations of the object (P>0.05, Fig. 2a) . Differentiation of exploratory activity in the choice trial indicated that the animals in all saline groups inspected the object in the novel location to a significantly greater degree than they did the object in the familiar position, suggesting unaffected spatial working memory (P<0.05, Fig. 2b ). However, rats tested soon after VPA administration and 30 d after VPA treatment were unable to distinguish between objects in familiar and novel locations during the choice trial (P>0.05, Fig. 2b ), but rats in the VPA withdrawal 45 d group were able to make such distinctions. This shows that a deficit in spatial working memory had persisted after VPA withdrawal in these groups, but spatial memory had improved by 45 d after VPA treatment. Further analysis using the preference for objects in familiar or novel locations (PI) in the choice trial showed significantly less preference in VPA 10 d or VPA withdrawal 30 d rats compared to 50% chance (mean±standard error of mean (SEM); control 10 d: (63.04±2.45)%; VPA Fig. 2d ).
Effect of VPA withdrawal on the number of proliferating cells in the SGZ
Quantification of Ki67-positive cells in the SGZ alongside the internal border of the hippocampal dentate gyrus (Figs. 3a-3c ) showed significant differences among groups (P<0.05, Fig. 3g ). Rats receiving VPA for 10 d had fewer Ki67-positive cells than saline-treated rats (mean±SEM; control 10 d: 1775±208; VPA 10 d: 1260±115; P<0.05, Fig. 3g) . Conversely, no significant difference was found between saline-and VPA-treated rats that were killed at either 30 Fig. 3g ).
Effect of VPA withdrawal on Notch1 and BDNF expression
Notch1 and BDNF protein expression was determined using western blotting (Fig. 4a) . The results 
Discussion
VPA, which is frequently administered as an anti-seizure and mood stabilizing drug, has been reported to produce mild to moderate learning and memory deficits in humans (Carpay et al., 2005; Senturk et al., 2007) . The present study confirmed our previous results, which show that clinically relevant doses of VPA decreased spatial working memory. This behavioral effect was linked to a decline in the cell division needed for neurogenesis in the hippocampus (Umka et al., 2010) . Moreover, VPA induces Fig. 3 Cell proliferation in the sub-granular zone (SGZ) of the dentate gyrus using Ki67-positive staining (a-f) In the SGZ, the nuclei of Ki67-positive cells were stained green and cells of the dentate gyrus were stained red. (g) Total numbers of Ki67-positive cells (mean±SEM, n=10) in the dentate gyrus were determined from cell counts. The number of Ki67-positive cells in the SGZ of rats receiving VPA was not significantly different from that of rats receiving saline (P>0.05) in both the VPA withdrawal 30 and 45 d groups. However, rats administered with VPA for 10 d showed a significantly lower number of Ki67-positive cells in comparison with the control 10 d group ( * P<0.05) (Note: for interpretation of the references to color in this figure legend, the reader is referred to the web version of this article) dendritic morphological alteration by decreasing dendritic length, branch nodes, and spine density on both apical and basal dendrites. VPA was also found to cause hippocampal-dependent memory loss in an animal study (Sgobio et al., 2010) . The hippocampus is a prime candidate for the site of action of VPA in causing cognitive decline as this structure is required for spatial working memory (Carrozzo et al., 2005) and recognition (Reed and Squire, 1997) . New neurons continue to be generated in the hippocampus. These newly formed granule cell neurons merge into the circuitry of the dentate gyrus, and are essential for spatial memory consolidation (Zhao et al., 2006; Imayoshi et al., 2008) . Some reports have revealed that VPA stimulates spatial learning and memory deficits, which are related to induced hippocampal neuronal apoptosis. These impairments are associated with up-regulation of the sphingosine 1-phosphate (S1P) signaling pathway and down-regulation of the Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) and cAMP-responsive element binding protein (CREB) signaling pathway (Wu et al., 2018) . The NOL test was selected as a measure of spatial memory, as successful performance of this test requires the hippocampus and exploits the natural habit of rats to prefer novelty. As such it does not require positive or negative reinforcement (Mumby et al., 2002) . This newness-preference model is similar to recognition memory in humans as detected in normal life (Ennaceur and Delacour, 1988) . In rodents and humans, the dentate gyrus within the hippocampus is required for spatial working memory. Lesion of this structure (n=10) prevents animals from successfully carrying out the NOL test (Dix and Aggleton, 1999) . VPA is thought to inhibit cell proliferation via the epigenetic mechanism of DNA hyperacetylation which causes cell cycle arrest due to increased expression of genes which inhibit mitosis (Kostrouchová et al., 2007) . Changes in cell division in the SGZ of the dentate gyrus correlate with changes in spatial memory ability (Seigers et al., 2008; Sirichoat et al., 2015; Welbat et al., 2016b) , making alterations in hippocampal neurogenesis a likely cause of the behavioral changes brought about by VPA.
Some studies have reported that even after taking VPA for long periods, patients can show improvements in memory after ceasing to take it (Louissaint et al., 2002; Masmoudi et al., 2006; Hommet et al., 2007) . This study was designed to see if this change could be replicated in an animal model in which the cognitive deficits of VPA treatment have previously been demonstrated, and to determine the time course of any improvements in cognition. Also, we wished to ascertain whether changes in spatial memory were correlated with changes in markers of hippocampal neurogenesis and neurotrophin levels which have been demonstrated to show a decline after VPA treatment.
Our results show that hippocampal-dependent spatial memory, as evaluated by the NOL test, was impaired after 10 d of VPA treatment, which is in line with our previous report (Umka et al., 2010) . This memory deficit remained at 30 d, but had returned to control levels within 45 d of the end of VPA treatment. This demonstrates that the memory deficit shown shortly after VPA treatment (Umka et al., 2010) can be reversed by withdrawal of VPA.
The level of proliferating cells in the subgranular zone of the dentate gyrus had returned to the control level within 30 d after discontinuing VPA administration, indicating that cell proliferation recovers faster than improvements in spatial memory. This reflects the time taken for new born neurons to become integrated into hippocampal circuitry, a process known to take one to two months (Zhao et al., 2006) . Similar to changes in cell proliferation, control values in the expression of BDNF and Notch1 in the hippocampus were present by 45 d post treatment.
Newly produced neurons in the SGZ develop into mature granule cells within four weeks of progenitor cell division (Zhao and Daley, 2008) . Recently formed (4-to 8-week-old) neurons are specifically recruited to form hippocampal circuits contributing to spatial memory (Kee et al., 2007) . This would suggest that discontinuation of VPA allows up-regulation of hippocampal neurogenesis which is followed by cognitive improvement after six weeks. It is at present unclear whether changes in BDNF precede or follow increases in cell proliferation in the SGZ. Up-regulation of BDNF levels could improve cell proliferation and survival with a subsequent reduction in memory deficits. Notch1 levels reflect the numbers and activation of neural stem cells. Levels of this receptor were similar to controls reflecting the normal levels of neurogenesis occurring after discontinuation of VPA treatment.
The present study shows that a period of recovery after discontinuation of VPA produces a significant improvement in cognitive performance compared to that found shortly after VPA treatment. This behavioral change is preceded by an increase in hippocampal neurogenesis and neurotrophin levels to control values. For patients who can stop taking VPA, these results indicate that this could have relatively rapid beneficial effects on memory.
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